Ress Life Investments A/S
27.3.2026 10:23:36 CET | Globenewswire | Press release
Ress Life Investments A/S announces the events of the extraordinary general meeting held on 27 March 2026
Ress Life Investments A/S announces the events of the extraordinary general meeting held on 27 March 2026
Ress Life Investments A/S
Nybrogade 12
DK-1203 Copenhagen K
Denmark
CVR nr. 33593163
www.resslifeinvestments.com
To: Nasdaq Copenhagen
Date: 27 March 2026
Corporate Announcement 12/2026
Ress Life Investments A/S announces the events of the extraordinary general meeting held on 27 March 2026.
At the extraordinary general meeting of Ress Life Investments A/S held on Friday 27 March 2026, the following decision was taken:
- Appointment of Deloitte Statsautoriseret Revisionspartnerselskab as auditor for the financial year 2025.
Questions related to this announcement can be made to the Company’s AIF-manager, Resscapital AB.
Contact person:
Johan Jonson
johan.jonson@resscapital.com
Tel + 46 70 612 02 14
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Chery Group8.10.2026 01:08:30 CEST | Press release
FREELANDER Details Powertrain, Battery and All-Terrain Technology for International Left-Hand Drive FREELANDER 8
Chongqing Changan Automobile Co., Ltd.7.10.2026 21:38:36 CEST | Press release
Changan Automobile to Make Major Announcements at Mondial de l'Auto 2026
Oma Säästöpankki Oyj7.10.2026 20:30:00 CEST | Press release
Notification under Chapter 9, Section 10 of the Securities Market Act: Holdings of S-Bank Plc in Oma Savings Bank Plc has exceeded 90 percent
Oma Säästöpankki Oyj7.10.2026 19:30:00 CEST | Press release
Notification under Chapter 9, Section 10 of the Securities Market Act: Holdings of Parkanon Säästöpankkisäätiö in Oma Savings Bank Plc has fallen below the flagging threshold
Zealand Pharma7.10.2026 19:13:53 CEST | Press release
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom